Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
Go back to Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress| (NASDAQ: ELDN) | Delayed: 3.74 +0.02 (0.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.72 | 52 Week High | $ | |||
| Open | $3.84 | 52 Week Low | $ | |||
| Day High | $3.84 | P/E | N/A | |||
| Day Low | $3.62 | EPS | $ | |||
| Volume | 614,382 | |||||
